title: TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.
abstract: Multiple myeloma (MM) is a B-cell malignancy characterized by an accumulation of abnormal clonal plasma cells in the bone marrow. Introduction of the proteasome-inhibitor bortezomib has improved MM prognosis and survival; however hypoxia-induced or acquired bortezomib resistance remains a clinical problem. This study highlighted the role of thioredoxin reductase 1 (TrxR1) in the hypoxia-induced and acquired bortezomib resistance in MM. Higher TrxR1 gene expression correlated with high-risk disease, adverse overall survival, and poor prognosis in myeloma patients. We demonstrated that hypoxia induced bortezomib resistance in myeloma cells and increased TrxR1 protein levels. Inhibition of TrxR1 using auranofin overcame hypoxia-induced bortezomib resistance and restored the sensitivity of hypoxic-myeloma cells to bortezomib. Hypoxia increased NF-кβ subunit p65 nuclear protein levels and TrxR1 inhibition decreased hypoxia-induced NF-кβ p65 protein levels in the nucleus and reduced the expression of NF-кβ-regulated genes. In addition, higher TrxR1 protein levels were observed in bortezomib-resistant myeloma cells compared to the naïve cells, and its inhibition using either auranofin or TrxR1-specific siRNAs reversed bortezomib resistance. TrxR1 inhibition reduced p65 mRNA and protein expression in bortezomib-resistant myeloma cells, and also decreased the expression of NF-кβ-regulated anti-apoptotic and proliferative genes. Thus, TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance by inhibiting the NF-кβ signaling pathway. Our findings demonstrate that elevated TrxR1 levels correlate with the acquisition of bortezomib resistance in MM. We propose considering TrxR1-inhibiting drugs, such as auranofin, either for single agent or combination therapy to circumvent bortezomib-resistance and improve survival outcomes of MM patients.
authors.affiliation: a School of Natural Sciences, Griffith University , Nathan , QLD , Australia.|b Eskitis Institute for Drug Discovery, Griffith University , Nathan , QLD , Australia.
authors.forename: Prahlad V
authors.initials: PV
authors.lastname: Raninga
authors.affiliation: a School of Natural Sciences, Griffith University , Nathan , QLD , Australia.
authors.forename: Giovanna
authors.initials: G
authors.lastname: Di Trapani
authors.affiliation: c QIMR Berghofer Medical Research Institute , Herston , QLD , Australia.|d School of Medicine, University of Queensland , Herston , QLD , Australia.
authors.forename: Slavica
authors.initials: S
authors.lastname: Vuckovic
authors.affiliation: a School of Natural Sciences, Griffith University , Nathan , QLD , Australia.|b Eskitis Institute for Drug Discovery, Griffith University , Nathan , QLD , Australia.
authors.forename: Kathryn F
authors.initials: KF
authors.lastname: Tonissen
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D001310:Auranofin / Q000008:administration & dosage; D000069286:Bortezomib / Q000008:administration & dosage; D015687:Cell Hypoxia / Q000187:drug effects / Q000235:genetics; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D016328:NF-kappa B / Q000235:genetics; D061988:Proteasome Inhibitors / Q000008:administration & dosage; D015398:Signal Transduction / Q000187:drug effects; D054481:Thioredoxin Reductase 1 / Q000096:biosynthesis / Q000235:genetics*
chemical_list: D016328:NF-kappa B; D061988:Proteasome Inhibitors; D001310:Auranofin; D000069286:Bortezomib; C516124:TXNRD1 protein, human; D054481:Thioredoxin Reductase 1
keywords: NF-кβ; Thioredoxin reductase; auranofin; bortezomib; drug resistance; hypoxia; multiple myeloma